DexCom (NASDAQ:DXCM) Price Target Cut to $87.00

DexCom (NASDAQ:DXCM) had its price objective reduced by Leerink Partners from $90.00 to $87.00 in a research note published on Friday morning, Benzinga reports. They currently have an outperform rating on the medical device company’s stock.

Several other equities research analysts have also commented on DXCM. Oppenheimer cut their price target on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, July 26th. Canaccord Genuity Group reiterated a “buy” rating and set a $145.00 price target on shares of DexCom in a research note on Tuesday, July 23rd. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, October 12th. JPMorgan Chase & Co. lowered shares of DexCom from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $145.00 to $75.00 in a research note on Friday, July 26th. Finally, Wells Fargo & Company lifted their price target on shares of DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday. Six analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $104.59.

DexCom Price Performance

DexCom stock opened at $72.10 on Friday. The stock has a market cap of $28.67 billion, a P/E ratio of 46.69, a price-to-earnings-growth ratio of 2.26 and a beta of 1.18. The company has a fifty day simple moving average of $70.11 and a 200-day simple moving average of $97.65. DexCom has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00.

Insider Transactions at DexCom

In other news, EVP Michael Jon Brown sold 652 shares of the business’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total transaction of $45,346.60. Following the transaction, the executive vice president now directly owns 66,249 shares in the company, valued at $4,607,617.95. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, EVP Michael Jon Brown sold 652 shares of the business’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total transaction of $45,346.60. Following the transaction, the executive vice president now directly owns 66,249 shares in the company, valued at $4,607,617.95. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,824 shares of company stock worth $126,390 over the last ninety days. 0.30% of the stock is currently owned by company insiders.

Institutional Trading of DexCom

Institutional investors have recently added to or reduced their stakes in the stock. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in DexCom during the second quarter worth about $25,000. Sachetta LLC boosted its holdings in DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after buying an additional 171 shares in the last quarter. Crewe Advisors LLC purchased a new stake in DexCom during the first quarter worth about $29,000. Riverview Trust Co boosted its holdings in DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after buying an additional 232 shares in the last quarter. Finally, DT Investment Partners LLC boosted its holdings in DexCom by 492.2% during the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after buying an additional 315 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.